Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K)

Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K) is a phase 2, interventional study registered as NCT07510932 by Korea University Anam Hospital, with a registry enrolment figure of 88 participants, started 2026-05-01 and due to reach its primary completion in 2027-03-01. Interventions recorded: Fruquintinib. Conditions listed: Colon Cancer. Primary outcome: Progression-free survival. Colorectal eligibility wording from the registry: "Documented irreversible surgical sterilization, including hysterectomy, bilateral oophorectomy, or bilateral salpingectomy". No results are recorded here; the registry entry is the source.